OBJECTIVE. The purpose of this article is to summarize the evidence regarding the role of
FDG PET/CT in treatment response assessment and surveillance of lung cancer and to …

Despite considerable improvements in the treatment options for advanced-stage non-small-
cell lung cancer (NSCLC), disease-specific survival remains poor. With the aim of improving …

Purpose Epidermal growth factor receptor (EGFR) mutations and the anaplastic lymphoma
kinase (ALK) rearrangement are the two most common druggable targets in non-small cell …

Tumor heterogeneity and changes in epidermal growth factor receptor (EGFR) mutation
status over time challenge the design of effective EGFR tyrosine kinase inhibitor (TKI) …

Development of new oncology drugs has increased since the improved understanding of
cancer's complex biology. The oncology field has become the top therapeutic research area …

Purpose The tumour molecular profile predicts the activity of epidermal growth factor
receptor (EGFR) inhibitors in non-small-cell lung cancer (NSCLC). However, tissue …

PET/CT with the tracer 2-[18 F] fluoro-2-deoxy-D-glucose ([18 F] FDG) has improved
diagnostic imaging in cancer and is routinely used for diagnosing, staging and treatment …

Despite the promising efficacy of immunotherapy in some patients, many other patients are
resistant. The synergistic effect of radiotherapy (RT) in combination with immunotherapy …

Multiple small molecule PET tracers have been developed for the imaging of the epidermal
growth factor receptor (EGFR). These tracers target the tyrosine kinase (TK) domain of the …

In an effort to discover a noninvasive method for predicting which cancer patients will benefit
from therapy targeting the EGFR and HER2 proteins, a large body of the research has been …